Cramer Shares His Thoughts On Stem, Marvell Technology And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology Inc (NASDAQ: MRVL) is the "best when it comes to 5G, the best in high-performance computing.
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell
• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
SVB Leerink Maintains Outperform on AbCellera Biologics, Lowers Price Target to $20
SVB Leerink analyst Puneet Souda maintains AbCellera Biologics (NASDAQ:ABCL) with a Outperform and lowers the price target from $25 to $20.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
Lilly’s Antibody Receives FDA Emergency Use Nod For Mild-To-Moderate COVID-19
The FDA on Friday authorized Eli Lilly And Co's (NYSE:
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization For Treatment Of Mild-To-Moderate COVID-19
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
Bebtelovimab (LY-CoV1404) neutralizes Omicron, including the subvariant BA.2,
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
AbCellera and Its Collaborators Released New Preclinical Data Confirming That the Investigational Antibody Bebtelovimab Maintains Both Full and Potent Neutralization Activity Against the Omicron Variant and All Other Known SARS-COV-2 Variants of Concer…
AbCellera and its collaborators released new preclinical data showing the pseudovirus neutralization status of its two monoclonal antibodies, bamlanivimab and bebtelovimab (also known as LY-CoV1404), against the Omicron variant.
